Ping Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ping Liu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Changjing Cai
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Hong Shen
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Shan Zeng
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Ying Han
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Yongting Liu
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China
2 shared publications - Ziyang Feng
Department of Oncology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications
Latest Publications
- Open Access
- 7 April 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 158, 106862
Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma
- 7 April 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 158, 106862
Open AccessLipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma
- Open Access
- 6 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1286
A Multi-Omics Analysis of NASH-Related Prognostic Biomarkers Associated with Drug Sensitivity and Immune Infiltration in Hepatocellular Carcinoma
Background: Nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is becoming a major health-related problem. The exploration of NASH-related prognostic biomarkers and therapeutic targets is necessary. Methods: Data were downloaded from the GEO database. The “glmnet” package was used to identify differentially expressed genes (DEGs). The prognostic model was constructed by the univariate Cox and LASSO regression analyses. Validation of the expression and prognosis by immunohistochemistry (IHC) in vitro. Drug sensitivity and immune cell infiltration were analyzed by CTR-DB and ImmuCellAI. Results: We constructed a prognostic model that identified the NASH-related gene set (DLAT, IDH3B, and MAP3K4), which was validated in a real-world cohort. Next, seven prognostic transcription factors (TFs) were identified. The prognostic ceRNA network included three mRNAs, four miRNAs, and seven lncRNAs. Finally, we found that the gene set was associated with drug response which was validated in six clinical trial cohorts. Moreover, the expression level of the gene set was inversely correlated with CD8 T cell infiltration in HCC. Conclusions: We established a NASH-related prognostic model. Upstream transcriptome analysis and the ceRNA network provided clues for mechanism exploration. The mutant profile, drug sensitivity, and immune infiltration analysis further guided precise diagnosis and treatment strategies.
- 6 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1286
Open AccessA Multi-Omics Analysis of NASH-Related Prognostic Biomarkers Associated with Drug Sensitivity and Immune Infiltration in Hepatocellular Carcinoma
Background: Nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is becoming a major health-related problem. The exploration of NASH-related prognostic biomarkers and therapeutic targets is necessary. Methods: Data were downloaded from the GEO database. The “glmnet” package was used to identify differentially expressed genes (DEGs). The prognostic model was constructed by the univariate Cox and LASSO regression analyses. Validation of the expression and prognosis by immunohistochemistry (IHC) in vitro. Drug sensitivity and immune cell infiltration were analyzed by CTR-DB and ImmuCellAI. Results: We constructed a prognostic model that identified the NASH-related gene set (DLAT, IDH3B, and MAP3K4), which was validated in a real-world cohort. Next, seven prognostic transcription factors (TFs) were identified. The prognostic ceRNA network included three mRNAs, four miRNAs, and seven lncRNAs. Finally, we found that the gene set was associated with drug response which was validated in six clinical trial cohorts. Moreover, the expression level of the gene set was inversely correlated with CD8 T cell infiltration in HCC. Conclusions: We established a NASH-related prognostic model. Upstream transcriptome analysis and the ceRNA network provided clues for mechanism exploration. The mutant profile, drug sensitivity, and immune infiltration analysis further guided precise diagnosis and treatment strategies.